Quadrant Capital Group’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Quadrant Capital Group’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-73	Closed	-$7.83K	–	2806
2023 Q1	$7.83K	Buy	+73	New	+$8.4K	﹤0.01%	2119

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Quadrant Capital Group's RXDX Position: Q2 2023 in Review

Quadrant Capital Group sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 73 shares — an estimated $7.83K sold.

Quadrant Capital Group first reported a position in RXDX in Q1 2023 and held it in 1 quarter. The position peaked at $7.83K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Quadrant Capital Group reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Quadrant Capital Group sold 73 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $7.83K.
Quadrant Capital Group first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
Quadrant Capital Group's Prometheus Biosciences, Inc. Common Stock position peaked at $7.83K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Quadrant Capital Group's 13F filing for Q2 2023, filed 10 Aug 2023.